CureVac GmbH - Product Pipeline Review – 2015 Now Available at iData Insights CureVac GmbH - Product Pipeline Review - 2015 Summary Global Markets Direct s, CureVac GmbH Product Pipeline Review - 2015 , provides an overview of the CureVac GmbHs pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of CureVac GmbHs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of CureVac GmbH including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of CureVac GmbHs human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the CureVac GmbHs pipeline products Reasons to buy Evaluate CureVac GmbHs strategic position with total access to detailed information on its product pipeline - Assess the growth potential of CureVac GmbH in its therapy areas of focus - Identify new drug targets and therapeutic classes in the CureVac GmbHs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of CureVac GmbH and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of CureVac GmbH - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of CureVac GmbH and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=124221/curevac-gmbh-product-pipeline-review-2015 1
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=124221/curevac-gmbh-product-pipeline-review-2015 Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 CureVac GmbH Snapshot 6 CureVac GmbH Overview 6 Key Information 6 Key Facts 6 CureVac GmbH - Research and Development Overview 7 Key Therapeutic Areas 7 CureVac GmbH - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Pipeline Products - Out-Licensed Products 14 Out-Licensed Products/Combination Treatment Modalities 15 CureVac GmbH - Pipeline Products Glance 16 CureVac GmbH - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 CureVac GmbH - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 CureVac GmbH - Drug Profiles 20 CV-9103 20 2
Product Description 20 Mechanism of Action 20 R&D Progress 20 CV-9104 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 CV-9201 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CV-7201 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 CV-8102 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Oligonucleotide for Cancer 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Oligonucleotide for Infectious Disease 27 Product Description 27 Mechanism of Action 27
3
R&D Progress 27 Oligonucleotide for Influenza Virus Infection 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 respiratory syncytial virus vaccine 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 HIV vaccine 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Oligonucleotide for Rotavirus Infection 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Oligonucleotide for Undisclosed Indication 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Oligonucleotides for Undisclosed Indication 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 tuberculosis vaccine 34 Product Description 34 4
Mechanism of Action 34 R&D Progress 34 Vaccine for Oncology 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 CureVac GmbH - Pipeline Analysis 36 CureVac GmbH - Pipeline Products by Target 36 CureVac GmbH - Pipeline Products by Route of Administration 37 CureVac GmbH - Pipeline Products by Molecule Type 38 CureVac GmbH - Recent Pipeline Updates 39 CureVac GmbH - Locations And Subsidiaries 42 Head Office 42 Other Locations & Subsidiaries 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44 Read More http://www.idatainsights.com/reports-landing-page.php?id=124221/curevac-gmbhproduct-pipeline-review-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing 5
reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
6